<unk> , sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings. Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. It is a second generation Bruton's tyrosine kinase inhibitor.<unk>  blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme,<unk>  is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.<unk>  was approved for medical use in the United States in 2017, and in the European Union in November 2020.
Acalabrutinib
Zanubrutinib
Tucatinib
Ponatinib
Imatinib
Afatinib
Neratinib
Selpercatinib